Search This Blog

Tuesday, September 29, 2026

Capricor 24‑month HOPE‑3 data show Deramiocel sharply slows upper-limb decline in Duchenne

 

Capricor 24‑month HOPE‑3 data show Deramiocel sharply slows upper-limb decline in Duchenne patients vs placebo ahead of Nov. 22 FDA decision

  • New 24‑month HOPE‑3 extension analysis also compares Deramiocel outcomes favorably against established Duchenne muscular dystrophy disease-progression models.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)